Short answer
Gossamer Bio, Inc. (GOSS) filed its Q2 2026 10-Q quarterly report on Aug 13, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $9M (down 19.6% year over year) with net income of $17M.
Q2 2026 key financials · XBRL
- Revenue
- $9M
- −19.6% YoY · −45.5% QoQ
- Net income
- $17M
- +144.2% YoY · +136.2% QoQ
- Operating margin
- -282.2%
- EPS (diluted)
- −$0.04
- +76.5% YoY · +80.0% QoQ
Source: XBRL data from the Gossamer Bio, Inc. (GOSS) Q2 2026 10-Q on SEC EDGAR. USD.
Gossamer Bio, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $9.2M, down $2.3M from $11.5M YoY
- Net income $16.9M vs net loss $38.3M YoY, driven by $43.9M debt-extinguishment gain
- Seralutinib largest R&D program at $25.9M vs $41.6M YoY
- Cash, equivalents and marketable securities $57.0M at June 30, 2026
- NDA submission planned for September 2026, with potential FDA decision in third quarter 2027
Risk Factors
- New debt risk triggered by June 2026 Exchange Offer: $65.174M 2030 Notes become due March 2, 2027 if 2027 Notes exceed $4.0M
- Regulatory risk: FDA may reject or require additional trials for seralutinib after PROSERA failed its primary endpoint
- Operational risk: July 2026 termination of Chiesi collaboration returned worldwide seralutinib rights but added milestone and royalty obligations
- Nasdaq compliance risk: bid price below $1.00 for 30 consecutive business days, with compliance deadline October 5, 2026
- Financial dilution risk: Exchange Offer issued 254,150,441 shares and 169,191,727 warrants, with further issuances possible
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Gossamer Bio, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.